Your browser doesn't support javascript.
loading
In vitro thrombogenicity testing of pulsatile mechanical circulatory support systems: Design and proof-of-concept.
Brockhaus, Moritz K; Behbahani, Mehdi J; Muris, Farina; Jansen, Sebastian V; Schmitz-Rode, Thomas; Steinseifer, Ulrich; Clauser, Johanna C.
Afiliación
  • Brockhaus MK; Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Behbahani MJ; Biomaterials Laboratory, Institute of Bioengineering, Aachen University of Applied Sciences, Campus Jülich, Aachen, Germany.
  • Muris F; Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Jansen SV; Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Schmitz-Rode T; Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Steinseifer U; Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Clauser JC; Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Artif Organs ; 45(12): 1513-1521, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34312890
ABSTRACT
Thrombogenic complications are a main issue in mechanical circulatory support (MCS). There is no validated in vitro method available to quantitatively assess the thrombogenic performance of pulsatile MCS devices under realistic hemodynamic conditions. The aim of this study is to propose a method to evaluate the thrombogenic potential of new designs without the use of complex in-vivo trials. This study presents a novel in vitro method for reproducible thrombogenicity testing of pulsatile MCS systems using low molecular weight heparinized porcine blood. Blood parameters are continuously measured with full blood thromboelastometry (ROTEM; EXTEM, FIBTEM and a custom-made analysis HEPNATEM). Thrombus formation is optically observed after four hours of testing. The results of three experiments are presented each with two parallel loops. The area of thrombus formation inside the MCS device was reproducible. The implantation of a filter inside the loop catches embolizing thrombi without a measurable increase of platelet activation, allowing conclusions of the place of origin of thrombi inside the device. EXTEM and FIBTEM parameters such as clotting velocity (α) and maximum clot firmness (MCF) show a total decrease by around 6% with a characteristic kink after 180 minutes. HEPNATEM α and MCF rise within the first 180 minutes indicate a continuously increasing activation level of coagulation. After 180 minutes, the consumption of clotting factors prevails, resulting in a decrease of α and MCF. With the designed mock loop and the presented protocol we are able to identify thrombogenic hot spots inside a pulsatile pump and characterize their thrombogenic potential.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboelastografía / Trombosis / Corazón Artificial Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Artif Organs Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tromboelastografía / Trombosis / Corazón Artificial Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Artif Organs Año: 2021 Tipo del documento: Article País de afiliación: Alemania
...